270 related articles for article (PubMed ID: 35398717)
1. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.
Stares M; Ding TE; Stratton C; Thomson F; Baxter M; Cagney H; Cumming K; Swan A; Ross F; Barrie C; Maclennan K; Campbell S; Evans T; Tufail A; Harrow S; Lord H; Laird B; MacKean M; Phillips I
ESMO Open; 2022 Apr; 7(2):100445. PubMed ID: 35398717
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab.
Stares M; Doyle E; Chapple S; Raynes G; MacDonald J; Barrie C; Laird B; MacKean M; Philips I
Lung Cancer; 2024 Mar; 189():107497. PubMed ID: 38295631
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
6. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
7. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
[TBL] [Abstract][Full Text] [Related]
8. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
10. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer.
Raynes G; Stares M; Low S; Haron D; Sarwar H; Abhi D; Barrie C; Laird B; Caledonian Cachexia Collaborative ; Phillips I; MacKean M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067207
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer.
Menekse S; Kut E; Almuradova E
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):86-94. PubMed ID: 37869953
[TBL] [Abstract][Full Text] [Related]
14. Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors.
Mahiat C; Bihin B; Duplaquet F; Stanciu Pop C; Dupont M; Vander Borght T; Rondelet B; Vanderick J; André B; Pirard L; Ocak S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835030
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
16. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
17. Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients.
Oku Y; Toyokawa G; Wakasu S; Kinoshita F; Takamori S; Watanabe K; Haratake N; Nagano T; Kosai K; Takada K; Fujimoto A; Higashijima K; Shiraishi Y; Tanaka K; Takeoka H; Okamoto M; Yamashita T; Shimokawa M; Shoji F; Yamazaki K; Okamoto T; Seto T; Ueda H; Takeo S; Nakashima N; Okamoto I; Takenaka T; Yoshizumi T
Cancer Med; 2023 Jul; 12(13):14327-14336. PubMed ID: 37211905
[TBL] [Abstract][Full Text] [Related]
18. Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer.
Ogura Y; Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Tani N; Sato I; Hirose K; Kato D; Takeda T
Thorac Cancer; 2021 Jan; 12(1):97-105. PubMed ID: 33124197
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
20. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]